双重抗骨质疏松药雷尼酸锶  

Strontium ranelate: an anti-osteoporotic drug with dual effects

作　　者：房德玉[1] 任天丽[1] 

机构地区：[1]南京医科大学附属无锡市第二人民医院,无锡214002

出　　处：《中国骨质疏松杂志》2013年第8期881-884,共4页Chinese Journal of Osteoporosis

摘　　要：不同于其他抗骨质疏松药,雷尼酸锶是新型具有双重药理作用的抗骨质疏松药物,即抑制骨吸收和促进骨形成。雷尼酸锶可改变骨微结构,增加骨密度和骨强度,从而降低骨折风险,改善患者生活质量。临床研究显示,它能降低绝经后骨质疏松患者椎体和非椎体骨折的风险,并具有作用长久、安全性好、耐受性好的特点。Unlike other anti-osteoporotic drugs, strontium ranelate （SR） is a novel anti-osteoporotic drug, which has unique dual effects on bone metabolism, including inhibiting bone resorption and promoting bone formation. SR can alter the bone microstructure, and increase the bone mineral density and bone strength. Thus, SR can reduce the risk of fractures and improve the life quality of the patients. Clinical researches reveal that SR can reduce the risk of vertebral and non-vertebral fractures in patients with postmenopausal osteoporosis. The effect of SR can maintain for a long time. The safety and tolerance of SR are good.

关 键 词：雷尼酸锶 骨质疏松 骨形成 骨吸收 

分 类 号：R589.5[医药卫生—内分泌]